This is a working overview of Nuclear receptor, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-03-14 and is reviewed periodically as new material appears.
Laboratory detection of cardarine typically involves sample preparation followed by chromatographic separation and mass spectrometric identification. Urine is the most common matrix for anti-doping tests, though blood and hair have also been explored. Methods can target the parent compound or its metabolites, depending on the expected window of detection. Reference standards are required for accurate quantification. Matrix effects and dilution can influence results, so laboratories use internal standards and validation protocols. The exact detection window varies with dose, route, and individual metabolism.
A common misconception is that cardarine has been proven safe for human use. In reality, human clinical data are limited, and long-term animal studies have raised concerns about cancer. Another misconception is that it is a supplement or vitamin-like compound. It is a synthetic research chemical with no approved medical indication. Scientific discussion often focuses on its mechanism and detection rather than therapeutic use. Regulatory and anti-doping literature treats it primarily as a prohibited substance.
Cardarine is explicitly prohibited by the World Anti-Doping Agency under the class of PPARδ agonists. Its presence in urine or blood samples can be detected using mass spectrometry-based methods, often liquid chromatography-tandem mass spectrometry. Athletes who test positive may face sanctions, including bans from competition. The compound is also regulated as a prescription-only or unapproved drug in many countries. Enforcement varies by jurisdiction, and some regions treat it as a controlled substance. Online sales may occur despite these restrictions, creating quality and legal risks.
Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.
PPARδ is a nuclear receptor that regulates gene expression related to fatty acid oxidation, glucose homeostasis, and mitochondrial function. GW501516 binds to this receptor with high affinity and activates downstream signaling in skeletal muscle and other tissues. Animal studies reported increased endurance and altered fuel preference, but human data remain limited and inconsistent. The precise relationship between receptor activation and observed physiological changes is still an area of active investigation. Researchers have also examined whether the compound affects inflammation or cell proliferation. No approved therapeutic indication exists for cardarine.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA as a PPARδ agonist. |
| Typical detection matrix | Urine | Most common sample for anti-doping analysis. |
| Common analytical method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry. |
| Common synonyms | GW501516, GSK-516, endurobol | Names found in research and fitness contexts. |
| Typical detection window | Variable | Depends on dose, route, and individual metabolism. |
Stability of GW501516 depends on form, temperature, light exposure, and moisture. Solid reference material is typically stored frozen or refrigerated in a desiccator and protected from light. Solutions in organic solvents such as dimethyl sulfoxide are often kept frozen in aliquots to reduce freeze-thaw cycling. Aqueous solubility is low, so aqueous stock solutions can be difficult to prepare without cosolvents. Degradation may appear as changes in chromatographic purity or mass spectral signal. Stability studies are needed to establish shelf life for any specific preparation.
Quality assessment for cardarine samples usually combines identity, purity, and impurity testing. Nuclear magnetic resonance spectroscopy and mass spectrometry can confirm molecular structure, while high-performance liquid chromatography estimates purity. Certificates of analysis from testing laboratories may list these results, but they do not establish safety or legality. In the absence of approved manufacturing, products sold online may contain the wrong compound, variable amounts, or unlisted contaminants. Independent verification is therefore central to analytical work and to interpreting any reported biological activity.
Laboratory detection of GW501516 commonly uses liquid chromatography coupled with tandem mass spectrometry. The method can identify the parent compound or its metabolites in urine and blood after sample cleanup. Protein precipitation, solid-phase extraction, or enzymatic hydrolysis may precede analysis, depending on the matrix. Reference standards are required for accurate quantification and confirmation. Because the compound is not approved, testing often occurs in anti-doping, forensic, or research settings rather than routine clinical care. Results are reported with limits of detection and quantification.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.
GW501516 binds and activates PPARδ, a nuclear receptor that influences transcription of genes involved in fatty acid oxidation and energy use. Activation shifts some metabolic pathways in preclinical models, which is why the compound has been studied for lipid disorders and exercise-related endpoints. The exact downstream effects in humans are incompletely mapped. PPARδ is expressed in many tissues, including skeletal muscle, liver, and adipose tissue, so broad activation may have varied consequences. Researchers continue to examine how selective or partial activation might alter the balance between benefits and risks.
Published human data are sparse and mostly come from early-phase trials. Those studies examined short-term changes in lipids, glucose, and exercise capacity, but they were not large enough to establish efficacy or long-term safety. Some animal experiments reported increased running endurance, yet such findings do not prove a performance benefit in people. Anti-doping laboratories detect GW501516 and its metabolites in urine or blood using liquid chromatography-tandem mass spectrometry. Detection windows depend on dose, sample type, and individual metabolism. The method is sensitive enough to identify trace residues in tested samples.
== Role in the immune system == The proteasome plays a straightforward but critical role in the function of the adaptive immune system. Peptide antigens are displayed by the major histocompatibility complex class I (MHC) proteins on the surface of antigen-presenting cells. These peptides are products of proteasomal degradation of proteins originated by the invading pathogen. Although constitutively expressed proteasomes can participate in this process, a specialized complex composed of proteins, whose expression is induced by interferon gamma, are the primary producers of peptides which are optimal in size and composition for MHC binding. These proteins whose expression increases during the immune response include the 11S regulatory particle, whose main known biological role is regulating the production of MHC ligands, and specialized β subunits called β1i, β2i, and β5i with altered substrate specificity. The complex formed with the specialized β subunits is known as the immunoproteasome. Another β5i variant subunit, β5t, is expressed in the thymus, leading to a thymus-specific "thymoproteasome" whose function is as yet unclear. The strength of MHC class I ligand binding is dependent on the composition of the ligand C-terminus, as peptides bind by hydrogen bonding and by close contacts with a region called the "B pocket" on the MHC surface. Many MHC class I alleles prefer hydrophobic C-terminal residues, and the immunoproteasome complex is more likely to generate hydrophobic C-termini.
==== Analysis and appreciation ==== Birzer, Bradley J. Cultural Repercussions: An In-Depth Examination of the Words, Ideas and Professional Life of Neil Peart, Man of Letters. Wordfire Press, 2015. ISBN 1614753547. Bowman, Durrell and Berti, Jim. Rush and Philosophy: The Heart and Mind United. Open Court Press, 2011. ISBN 978-0812697162. Bowman, Durrell. Experiencing Rush: A Listener's Companion. Rowman & Littlefield Publishers, 2014. ISBN 1442231300. Freedman, Robert. Rush: Life, Liberty, and the Pursuit of Excellence. Algora Pub, 2014. ISBN 1628940840. McDonald, Chris. Rush, Rock Music, and the Middle Class: Dreaming in Middletown. Indiana University Press, 2009. ISBN 0-253-22149-8. Mobley, Max. Rush FAQ: All That's Left to Know About Rock's Greatest Power Trio. Backbeat Books, 2014. ISBN 1617134511. Popoff, Martin. Rush: Album by Album. Voyageur Press, 2017. ISBN 978-0760352205. Price, Carol S. and Robert M. Price. Mystic Rhythms: The Philosophical Vision of Rush. Wildside Press, 1999. ISBN 1-58715-102-2. Roberto, Leonard. A Simple Kind Mirror: The Lyrical Vision of Rush. Iuniverse Star, 2000. ISBN 0595213626. Telleria, Robert. Rush Tribute: Merely Players. Quarry Press, 2002. ISBN 1-55082-271-3.
Nearly 20,000 suspected armed OLF members, some of which were believed to be unarmed civilians (including children) were forcibly held in military camps in three different regions for the purpose of disarming and "re-educat[ing]" them, although very few had been released by the end of 1992. Throughout this time, the country's judiciary had failed to adequately adjudicate cases or to hold the TGE and its forces accountable for rights abuses. This was largely due to disruptions such as the looming threat of a possible suspension of all judges who were associated with the former Workers' Party of Ethiopia, the abrupt resignation of the Minister of Justice, a lack of an operating police force. These types of abuses persisted throughout the remainder of the transitional period. Freedom of the press was limited; in the first half of 1994, at least twenty journalists were fined or jailed as a result of publishing content that challenged the government, a situation exacerbated by the fact that the contemporary press laws were vague and improperly implemented. Human rights organizations including the Ethiopian Human Rights Council were denied formal registration from the government but continued to process complaints and report abuses; the government accused EHRCO of being a politically-motivated group with a hidden agenda that favored opposition groups and reported false information. Individuals suspected to have been previously associated with the OLF were treated particularly harshly once they were detained in secret detention centers across the country.
Sources: en.wikipedia.org
=== Vacuum systems === SSIMS experiments are performed in high vacuum for two reasons: first, to avoid scattering of the primary and secondary beams, and second, to prevent interfering adsorption of gases (i.e. oxygen) on the surface under investigation. For the first requirement, a pressure lower than 10−5 mbar is sufficient to ensure a mean free path that is long compared with the beam path. One monolayer of gas forms in 1 second at a pressure of 10−6 mbar. Thus for SSIMS analyses a pressure of ~ 10−10 mbar is needed to allow adequate time to complete the experiment.
== Applications == To date, PAMPA models have been developed that exhibit a high degree of correlation with permeation across a variety of barriers, including Caco-2 cultures, the gastrointestinal tract, blood–brain barrier and skin. The donor and/or acceptor compartments may contain solubilizing agents, or additives that bind the drugs as they permeate. To improve the in vitro - in vivo correlation and performance of the PAMPA method, the lipid, pH and chemical composition of the system is often designed with biomimetic considerations in mind. Although active transport is not modeled by the artificial PAMPA membrane, up to 95% of known drugs are absorbed by passive transport. Some experts support a lower figure, so the amount is open to some interpretation. Microtiter plates with 96 wells can be used for the assay which increases the speed and lowers the per sample cost.
In 2005 MeMe Roth began an obesity campaign that led to several appearances in American mainstream media. Programs such as Eat Smart, Move More, Weigh Less, developed in 2007 by writing teams from North Carolina State University and North Carolina Division of Public Health, and now available beyond North Carolina, aim to combat obesity by a combination of healthy eating and increased exercise. In 2008, the state of Pennsylvania enacted a law, the "School Nutrition Policy Initiative," aimed at the elementary level. These "interventions included removing all sodas, sweetened drinks, and unhealthy snack foods from selected schools, 'social marketing' to encourage the consumption of nutritious foods and outreach to parents." The results were a "50 percent drop in incidence of obesity and overweight", as opposed to those individuals who were not part of the study. In the past decade, there have been school-based programs that target the prevention and management of childhood obesity. There is evidence that long term school-based programs have been effective in reducing the prevalence of childhood obesity. For two years, Duke University psychology and global health professor Gary Bennett and eight colleagues followed 365 obese patients who had already developed hypertension. They found that regular medical feedback, self-monitoring, and a set of personalized goals can help obese patients in a primary care setting lose weight and keep it off. Major U.S.
A moderate degree of iron-deficiency anemia affects approximately 610 million people worldwide or 8.8% of the population. It is slightly more common in females (9.9%) than males (7.8%). Up to 15% of children ages 1–3 years have iron deficiency anemia. Mild iron deficiency anemia affects another 375 million. Iron deficiency affects up to 52% of pregnant women worldwide. The prevalence of iron deficiency as a cause of anemia varies among countries; in the groups in which anemia is most common, including young children and a subset of non-pregnant women, iron deficiency accounts for a fraction of anemia cases in these groups (25% and 37%, respectively). Iron deficiency is common in pregnant women. Within the United States, iron-deficiency anemia affects about 2% of adult males, 10.5% of White women, and 20% of African-American and Mexican-American women. A study in 2024 suggests that nearly 1 in 3 Americans may have undiagnosed iron deficiency, which can cause fatigue, brain fog, and concentration problems. The analysis of data from over 8,000 U.S. adults found that 14% had low iron levels, known as absolute iron deficiency; 15% had normal iron levels but their bodies couldn't effectively use the mineral, a condition called functional iron deficiency. A map provides a country-by-country listing of what nutrients are fortified into specified foods. Some of the Sub-Saharan countries shown in the deaths from iron-deficiency anemia map from 2012 are, as of 2018, fortifying foods with iron.
Sources: en.wikipedia.org
Yes, WADA prohibits cardarine as a PPARδ agonist. It appears on the prohibited list and can be detected in urine or blood. Athletes using it risk sanctions.
Detection usually uses liquid chromatography-tandem mass spectrometry after sample cleanup. Laboratories look for the parent compound or metabolites. The method requires validated reference standards and controls.
Legality varies by country. In many places it is an unapproved drug and cannot be legally sold for human consumption. Purchasing from online vendors carries legal and quality risks.
Cardarine is a common name for GW501516, a synthetic PPARδ agonist developed for research. It has not been approved as a medication in any country. It is classified as an unapproved drug and a prohibited substance in sport.